The inevitable QSAR renaissance (scientific article published on 30 November 2011)

Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: alleviating drug-drug interactions through use of PubChem data and comparative molecular field analysis guided synthesis.

Q33901205

Integration of diverse data sources for prediction of adverse drug events

Q34052007

Pushing the boundaries of 3D-QSAR.

Q36718321

How not to develop a quantitative structure-activity or structure-property relationship (QSAR/QSPR).

Q37526685

How to recognize and workaround pitfalls in QSAR studies: a critical review

Q37597312

Modeling approaches for ligand-based 3D similarity.

Q37855896

Rethinking 3D-QSAR.

Q42661891

Capturing structure-activity relationships from chemogenomic spaces

Q43730069

Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using Topomer CoMFA.

Q45393672

Quantitative Series Enrichment Analysis (QSEA): a novel procedure for 3D-QSAR analysis.

Q51892184

Substructural analysis. Novel approach to the problem of drug design

Q52908354

On model building in structure-activity relationships. A reexamination of adrenergic blocking activity of beta-halo-beta-arylalkylamines.

Q52940373

The trouble with QSAR (or how I learned to stop worrying and embrace fallacy)

Q80416269

SAMFA: simplifying molecular description for 3D-QSAR

Q81336641

3D-QSAR illusions

Q81437679

Is QSAR relevant to drug discovery?

Q82811393

Why you should read Dr. Cramer's perspective

Q83380497

P433

issue

P304

page(s)

35-38

P577

publication date

2011-11-30

P1433

published in

Journal of Computer - Aided Molecular Design

Q15766522

P1476

title

The inevitable QSAR renaissance

P478

volume

Reverse relations

cites work (P2860)

Q38867278	A Round Trip from Medicinal Chemistry to Predictive Toxicology
Q49226937	A perspective on multi-target drug discovery and design for complex diseases.
Q38206286	Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents.
Q30352841	Antiprotozoal Nitazoxanide Derivatives: Synthesis, Bioassays and QSAR Study Combined with Docking for Mechanistic Insight.
Q38615086	Aromatase inhibitory activity of 1,4-naphthoquinone derivatives and QSAR study.
Q92899539	BCL::Mol2D-a robust atom environment descriptor for QSAR modeling and lead optimization
Q26745421	Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies
Q38465124	In silico tools used for compound selection during target-based drug discovery and development
Q51092695	Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches.
Q93047984	Meta-QSAR: a large-scale application of meta-learning to drug design and discovery
Q38559373	Mind the Gap! A Journey towards Computational Toxicology
Q88878929	Performance of Machine Learning Algorithms for Qualitative and Quantitative Prediction Drug Blockade of hERG1 channel
Q93202753	Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process
Q28222668	QSAR modeling: where have you been? Where are you going to?
Q38630598	QSAR studies in the discovery of novel type-II diabetic therapies
Q47549119	Quantitative Structure-Activity Relationship Model for HCVNS5B inhibitors based on an Antlion Optimizer-Adaptive Neuro-Fuzzy Inference System
Q89761451	Targeting Tumors Using Peptides
Q36848213	Three-dimensional QSAR analysis and design of new 1,2,4-oxadiazole antibacterials

P8978	DBLP publication ID	journals/jcamd/Cramer12
P356	DOI	10.1007/S10822-011-9495-0
P2888	exact match	https://scigraph.springernature.com/pub.10.1007/s10822-011-9495-0
P932	PMC publication ID	3268966
P698	PubMed publication ID	22127732
P5875	ResearchGate publication ID	51840494